9 Meters Biopharma Inc expected to post a loss of 82 cents a share - Earnings Preview

9 Meters Biopharma

17/03/2023 12:34

* 9 Meters Biopharma Inc  NMTR.OQ   NMTR.O  is expected
to show no
change in quarterly revenue when it reports  results on March 21
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for 9 Meters Biopharma
Inc is
for a loss of 82 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for 9 Meters
Biopharma Inc is $38​, above​ its last closing price of $1.41.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.83       -0.82      -0.72     Beat    12.2
 Jun. 30 2022  -0.90       -0.83      -0.80     Beat    4
 Mar. 31 2022  -0.80       -0.75      -0.80     Missed  -6.7​
 Dec. 31 2021              -0.72      -0.80     Missed  -11.1
 ​​Sep.        -0.89       -0.73      -1.00     Missed  -36.4
 30 2021                                                
 Jun. 30 2021  -0.60       -0.60      -0.60     Met     0​
 Mar. 31 2021  -0.55       -0.55      -0.60     Missed  -9.1
 Dec. 31 2020  -0.90       -0.82      -1.00     Missed  -21.2
 This summary was machine generated March 17 at 12:33 GMT.  All
figures in US dollars  unless otherwise stated